Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.03 Million USD | -27.16% |
| 2022 | -15.6 Million USD | -10.68% |
| 2021 | -14.26 Million USD | -58.74% |
| 2020 | -8.94 Million USD | -23.78% |
| 2019 | -7.38 Million USD | -70.67% |
| 2018 | -4.24 Million USD | -10.77% |
| 2017 | -3.82 Million USD | -18.43% |
| 2016 | -4.08 Million USD | -54.32% |
| 2015 | -2.23 Million USD | -411.49% |
| 2014 | -406.56 Thousand USD | -170.89% |
| 2013 | 486.81 Thousand USD | 82.38% |
| 2012 | 303.64 Thousand USD | 863.64% |
| 2011 | -39.21 Thousand USD | -557.47% |
| 2010 | 12.71 Thousand USD | 105.03% |
| 2009 | -172.54 Thousand USD | -44.94% |
| 2008 | -188.54 Thousand USD | -163.04% |
| 2007 | 218.03 Thousand USD | -21.4% |
| 2006 | -63.31 Thousand USD | 197.83% |
| 2005 | -77.6 Thousand USD | -1423.25% |
| 2004 | -251.15 Thousand USD | -83.34% |
| 2003 | 90.91 Thousand USD | -47.64% |
| 2002 | 221.54 Thousand USD | 790.39% |
| 2001 | 27.58 Thousand USD | 109.4% |
| 2000 | -66.02 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.63 Million USD | -10.35% |
| 2024 Q1 | -5.1 Million USD | 9.41% |
| 2023 FY | - USD | -27.16% |
| 2023 Q1 | -5 Million USD | -0.85% |
| 2023 Q2 | -4.62 Million USD | 7.55% |
| 2023 Q4 | -5.63 Million USD | -18.47% |
| 2023 Q3 | -4.75 Million USD | -2.9% |
| 2022 Q1 | -3.09 Million USD | -12.61% |
| 2022 FY | - USD | -10.68% |
| 2022 Q4 | -4.95 Million USD | -16.84% |
| 2022 Q3 | -4.24 Million USD | -22.85% |
| 2022 Q2 | -3.45 Million USD | -11.73% |
| 2021 Q3 | -3.85 Million USD | -7.08% |
| 2021 Q2 | -3.59 Million USD | 10.8% |
| 2021 FY | - USD | -58.74% |
| 2021 Q1 | -4.03 Million USD | -50.54% |
| 2021 Q4 | -2.74 Million USD | 28.74% |
| 2020 Q2 | -2.2 Million USD | 16.67% |
| 2020 FY | - USD | -23.78% |
| 2020 Q3 | -1.43 Million USD | 35.02% |
| 2020 Q4 | -2.67 Million USD | -86.98% |
| 2020 Q1 | -2.64 Million USD | -13.52% |
| 2019 Q1 | -1.9 Million USD | -42.17% |
| 2019 Q3 | -1.63 Million USD | -18.93% |
| 2019 Q4 | -2.33 Million USD | -43.0% |
| 2019 FY | - USD | -70.67% |
| 2019 Q2 | -1.37 Million USD | 28.21% |
| 2018 Q1 | -813.3 Thousand USD | 41.01% |
| 2018 Q3 | -789.67 Thousand USD | 39.15% |
| 2018 Q4 | -1.34 Million USD | -70.13% |
| 2018 FY | - USD | -10.77% |
| 2018 Q2 | -1.29 Million USD | -59.56% |
| 2017 Q2 | -828.6 Thousand USD | 16.26% |
| 2017 Q1 | -989.54 Thousand USD | -29.52% |
| 2017 Q4 | -1.37 Million USD | -117.3% |
| 2017 FY | - USD | -18.43% |
| 2017 Q3 | -634.48 Thousand USD | 23.43% |
| 2016 Q4 | -764 Thousand USD | 4.13% |
| 2016 Q1 | -687.41 Thousand USD | 21.04% |
| 2016 FY | - USD | -54.32% |
| 2016 Q2 | -1.02 Million USD | -48.41% |
| 2016 Q3 | -796.94 Thousand USD | 21.89% |
| 2015 Q2 | -313.09 Thousand USD | 8.44% |
| 2015 Q1 | -341.94 Thousand USD | -24.53% |
| 2015 Q4 | -870.63 Thousand USD | -52.54% |
| 2015 FY | - USD | -411.49% |
| 2015 Q3 | -570.75 Thousand USD | -82.3% |
| 2014 FY | - USD | -170.89% |
| 2014 Q1 | 196.05 Thousand USD | 708.08% |
| 2014 Q4 | -274.57 Thousand USD | -75.0% |
| 2014 Q3 | -156.89 Thousand USD | 10.06% |
| 2014 Q2 | -174.45 Thousand USD | -188.98% |
| 2013 Q3 | -62.05 Thousand USD | -115.36% |
| 2013 Q4 | 24.26 Thousand USD | 139.1% |
| 2013 Q2 | 404.03 Thousand USD | 90.67% |
| 2013 Q1 | 211.9 Thousand USD | -4.42% |
| 2013 FY | - USD | 82.38% |
| 2012 Q3 | 7403.00 USD | 125.76% |
| 2012 Q4 | 221.7 Thousand USD | 2894.81% |
| 2012 Q2 | -28.74 Thousand USD | -124.64% |
| 2012 Q1 | 116.62 Thousand USD | 198.42% |
| 2012 FY | - USD | 863.64% |
| 2011 FY | - USD | -557.47% |
| 2011 Q1 | 1375.00 USD | -98.06% |
| 2011 Q2 | 47.44 Thousand USD | 3350.47% |
| 2011 Q3 | 28.16 Thousand USD | -40.63% |
| 2011 Q4 | -118.49 Thousand USD | -520.69% |
| 2010 Q3 | -6205.00 USD | -120.49% |
| 2010 Q1 | -102.61 Thousand USD | 35.52% |
| 2010 FY | - USD | 105.03% |
| 2010 Q2 | 30.28 Thousand USD | 129.52% |
| 2010 Q4 | 70.76 Thousand USD | 1240.39% |
| 2009 Q3 | 35.09 Thousand USD | 599.67% |
| 2009 FY | - USD | -44.94% |
| 2009 Q1 | -49.3 Thousand USD | -1066.04% |
| 2009 Q2 | -7023.00 USD | 85.75% |
| 2009 Q4 | -159.12 Thousand USD | -553.46% |
| 2008 Q1 | -85.03 Thousand USD | -246.24% |
| 2008 Q4 | -4228.00 USD | 69.64% |
| 2008 Q3 | -13.92 Thousand USD | 34.45% |
| 2008 Q2 | -21.24 Thousand USD | 75.01% |
| 2008 FY | - USD | -163.04% |
| 2007 Q3 | 61.47 Thousand USD | -24.42% |
| 2007 FY | - USD | -21.4% |
| 2007 Q4 | 58.14 Thousand USD | -5.41% |
| 2007 Q2 | 81.33 Thousand USD | 2410.77% |
| 2007 Q1 | -3520.00 USD | -101.94% |
| 2006 Q2 | -3098.00 USD | -103.84% |
| 2006 FY | - USD | 197.83% |
| 2006 Q4 | 181.85 Thousand USD | 2317.42% |
| 2006 Q3 | -8201.00 USD | -164.72% |
| 2006 Q1 | 80.58 Thousand USD | 138.12% |
| 2005 FY | - USD | -1423.25% |
| 2005 Q1 | -204.18 Thousand USD | -755.77% |
| 2005 Q2 | 20.55 Thousand USD | 110.07% |
| 2005 Q3 | -68.05 Thousand USD | -431.07% |
| 2005 Q4 | -211.4 Thousand USD | -210.64% |
| 2004 Q4 | 31.13 Thousand USD | 482.88% |
| 2004 FY | - USD | -83.34% |
| 2004 Q3 | -8132.00 USD | -180.82% |
| 2004 Q2 | 10.06 Thousand USD | -38.67% |
| 2004 Q1 | 16.4 Thousand USD | -68.21% |
| 2003 Q1 | -691.00 USD | 97.63% |
| 2003 FY | - USD | -47.64% |
| 2003 Q4 | 54.38 Thousand USD | 40.66% |
| 2003 Q3 | 37.84 Thousand USD | 15.08% |
| 2003 Q2 | 31.88 Thousand USD | 4714.62% |
| 2002 Q4 | -20.61 Thousand USD | -141.85% |
| 2002 Q2 | 54.12 Thousand USD | -70.79% |
| 2002 Q1 | 103.53 Thousand USD | 2100.11% |
| 2002 Q3 | 84.5 Thousand USD | 62.08% |
| 2002 FY | - USD | 790.39% |
| 2001 Q2 | 22.99 Thousand USD | 259.28% |
| 2001 Q1 | 10.37 Thousand USD | 89.79% |
| 2001 FY | - USD | 109.4% |
| 2001 Q4 | -8134.00 USD | -508.37% |
| 2001 Q3 | 2375.00 USD | -88.09% |
| 2000 Q3 | -13.51 Thousand USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q4 | -90.88 Thousand USD | -58.43% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 106.497% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -752.007% |
| Embecta Corp. | 245.4 Million USD | 108.163% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 112.297% |
| PainReform Ltd. | -9.56 Million USD | -109.33% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -423.76% |
| SCYNEXIS, Inc. | 73.47 Million USD | 127.261% |
| Journey Medical Corporation | 1.92 Million USD | 1142.727% |
| Safety Shot Inc | -12.18 Million USD | -64.386% |
| Alpha Teknova, Inc. | -25.53 Million USD | 21.568% |
| Bright Green Corporation | - USD | Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 119.255% |
| Alvotech | -484.86 Million USD | 95.869% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 118.323% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 1794.652% |
| Cosmos Health Inc. | -17.06 Million USD | -17.401% |
| Dynavax Technologies Corporation | 9.66 Million USD | 307.229% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 86.656% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 87.39% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -423.76% |
| Theratechnologies Inc. | -10.31 Million USD | -94.232% |
| Harrow Health, Inc. | 9.72 Million USD | 306.014% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -342.669% |
| Biofrontera Inc. | -18.45 Million USD | -8.55% |
| DURECT Corporation | -24.68 Million USD | 18.851% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 120.385% |
| Cronos Group Inc. | -72.14 Million USD | 72.237% |
| OptiNose, Inc. | -15.55 Million USD | -28.79% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 97.834% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 44.485% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 176.261% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 155.593% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -410.683% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -2717.863% |
| Radius Health, Inc. | 38.31 Million USD | 152.286% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -523.028% |
| ProPhase Labs, Inc. | -14.82 Million USD | -35.097% |
| Phibro Animal Health Corporation | 84.6 Million USD | 123.675% |
| Procaps Group S.A. | 104.02 Million USD | 119.255% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -138.433% |
| Viatris Inc. | 3.51 Billion USD | 100.57% |
| Rockwell Medical, Inc. | -4.69 Million USD | -326.732% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -1879.326% |
| SIGA Technologies, Inc. | 84.15 Million USD | 123.801% |
| Tilray Brands, Inc. | -72.84 Million USD | 72.501% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 2566.845% |
| Shineco, Inc. | -26.55 Million USD | 24.566% |
| PetIQ, Inc. | 81.48 Million USD | 124.582% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -453.699% |
| Incannex Healthcare Limited | -18.5 Million USD | -8.251% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 104.814% |
| Alimera Sciences, Inc. | 7.27 Million USD | 375.299% |
| Silver Spike Investment Corp. | 7.34 Million USD | 372.895% |
| Assertio Holdings, Inc. | -222.44 Million USD | 90.995% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -401.943% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -375.579% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -19.202% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 86.568% |
| Hempacco Co., Inc. | -12.77 Million USD | -56.818% |
| Talphera, Inc. | -9.84 Million USD | -103.523% |
| Alvotech | -484.86 Million USD | 95.869% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 125.846% |
| Lantheus Holdings, Inc. | 491 Million USD | 104.08% |
| Currenc Group, Inc. | -1.9 Million USD | -953.933% |
| Kamada Ltd. | 21.53 Million USD | 193.019% |
| Indivior PLC | 66 Million USD | 130.35% |
| Evoke Pharma, Inc. | -7.29 Million USD | -174.684% |
| Flora Growth Corp. | -45.87 Million USD | 56.331% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -0.0% |
| Evolus, Inc. | -41.81 Million USD | 52.091% |
| HUTCHMED (China) Limited | 25.52 Million USD | 178.466% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 108.296% |
| Akanda Corp. | -27.73 Million USD | 27.78% |